Femasys Inc. (FEMY) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Femasys Inc. is a biomedical company focused on women's reproductive health, specifically infertility solutions (FemaSeed, FemVue) and permanent birth control (FemBloc). The company operates as a single segment and is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | Balance Sheet (June 30, 2024) |
|---|---|---|---|
| Sales | $221,484 | $492,624 | N/A |
| Net Loss | $(4,684,574) | $(8,284,084) | N/A |
| Loss Per Share (Basic/Diluted) | $(0.21) | $(0.38) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $13,525,898 |
| Convertible Notes Payable (Net) | N/A | N/A | $4,758,017 |
| Accumulated Deficit | N/A | N/A | $(116,665,713) |
| Operating Cash Flow | N/A | $(8,894,780) | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Sales decreased 30.9% quarter-over-quarter (Q2 2024 vs. Q2 2023) and 19.8% year-to-date, primarily due to the timing of international sales and a 41.7% drop in units sold.
- Expense Increases:
- Sales & Marketing: Surged 656.6% QoQ and 241.3% YTD due to hiring a commercial team for the FemaSeed launch.
- R&D: Increased 29.4% QoQ and 22.3% YTD, driven by higher clinical costs and material development for FemBloc.
- Interest Expense: Rose significantly due to the amortization of debt discounts and issuance costs related to the November 2023 convertible notes.
- Liquidity: Cash reserves decreased from $21.7 million (Dec 31, 2023) to $13.5 million (June 30, 2024), a reduction of approximately $8.2 million driven by operating losses.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for at least one year from the filing date. Current cash is projected to be sufficient only into July 2025, but additional financing is required to fund operations and the FemBloc clinical trial.
- Product Pipeline:
- FemaSeed: Received FDA 510(k) clearance and EU MDR/CE Mark certification. Commercial launch is underway with the first commercial procedure announced in March 2024.
- FemBloc: Pivotal clinical trial (FINALE) is actively enrolling at six sites. The trial aims to evaluate safety and efficacy for permanent birth control.
- Financing Needs: The company relies on existing cash, revenue from FemVue/FemaSeed, and future equity/debt financing. Failure to secure additional capital could force the termination of development activities.
- Debt Obligations: The company holds $6.85 million in principal convertible notes maturing in November 2025, with significant non-cash interest expense impacting net loss.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash depletion and the status of any new financing discussions.
- FemaSeed Commercialization: Monitor actual revenue recognition from FemaSeed sales, which are expected to commence in the second half of 2024.
- FemBloc Trial Progress: Track enrollment rates and interim safety data readouts for the pivotal FemBloc trial.
- Dilution Risk: Review the terms of the outstanding convertible notes and warrants (approx. 15 million potential shares) which could significantly dilute existing shareholders upon conversion or exercise.
- Going Concern Status: Assess the likelihood of securing the necessary capital to avoid operational delays or liquidation.